Start
•
Completion

Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate (Psilocin-1)

CompletedRegisteredCTG

Phase I open-label single-group study (n=10) assessing safety, tolerability and pharmacokinetics of a single oral L-130 capsule (psilocin mucate; reported 4 mg) in healthy male volunteers under fasting conditions.

Details

Open-label, single-group First-in-Man study to determine safety, pharmacokinetics and bioavailability of psilocin mucate (L-130) after a single oral fasting dose in healthy male volunteers (n=10).

Subjects were hospitalised for PK sampling with pre-dose and 13 post-dose blood samples over 24 hours; safety monitoring included vital signs, ECG, MMSE at ~2 hours, AE queries, and follow-up phone calls at 1 week and 4 weeks.

Topics:Healthy Volunteers

Registry

Registry linkNCT06035900